1.56
Q 32 Bio Inc Aktie (QTTB) Neueste Nachrichten
Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug - MSN
Layoff Tracker: BMS Closes Manufacturing Plant, Arvinas Axes One-Third of Staff - BioSpace
Analysts Provide Insight Into Q32 Bio Inc’s (QTTB) Potential. - Stocksregister
Closing Figures: Q32 Bio Inc (QTTB)’s Positive Finish at 1.60, Up 2.89 - DWinneX
Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug By Stocktwits - Investing.com India
Fierce Biotech Layoff Tracker 2025: Pliant cuts 45% of workforce; Arvinas lays off a third of staffers - Fierce Biotech
Q32 Bio Inc (NASDAQ: QTTB) Prices Could Soar To Much Higher Levels In Coming Months - Marketing Sentinel
Evaluating QTTB’s financial ratios for a profitable investment - uspostnews.com
Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata - marketscreener.com
Q32 Bio Inc. Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - marketscreener.com
Scotiabank Has Lowered Expectations for goeasy (TSE:GSY) Stock Price - American Banking and Market News
Analysts Set Q32 Bio Inc. (NASDAQ:QTTB) PT at $24.71 - Defense World
Q32 Bio announces board member resignation By Investing.com - Investing.com Nigeria
Q32 Bio IncMark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025 - marketscreener.com
Q32 Bio Board Member Mark Iwicki Resigns - TipRanks
Q32 Bio announces board member resignation - Investing.com
Can Sezzle Inc (NASDAQ: SEZL) Still Be Considered A Loss When It’s Up 5.08% YTD? - Marketing Sentinel
Q32 Bio doses first patient in both parts of SIGNAL-AA trial - TipRanks
Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial - marketscreener.com
Breakthrough: Q32 Bio's Alopecia Treatment Maintains Effects 7 Months After Last Dose - Stock Titan
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - PR Newswire
Raymond James Financial Inc. Buys New Stake in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio Files For Mixed Shelf Of Up To $200 MillionSEC Filing - MarketScreener
Wayfair Inc (NYSE: W) Has Dropped -40.68% Year-To-Date (YTD): Any Trouble Coming? - Marketing Sentinel
QTTB stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa
All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy - MSN
QTTB stock touches 52-week low at $1.38 amid market challenges - Investing.com India
Arbe Robotics Ltd (NASDAQ: ARBE): How To Buy And When To Buy And Its Performance & Trends - Marketing Sentinel
Russell hits bear market with small caps buffeted by tariff wave - The Edge Malaysia
Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.71 Average Target Price from Brokerages - Defense World
Biotech layoff tracker: 21 companies cut 1,000 jobs in Q1 2025 - The Business Journals
QTTB stock touches 52-week low at $1.79 amid market challenges By Investing.com - Investing.com South Africa
QTTB stock touches 52-week low at $1.79 amid market challenges - Investing.com India
Immunosuppressive and Anti-complement Therapies in C3 Glomerulopathy - Medscape
Immunosuppressive Therapies in C3 Glomerulopathy - Medscape
Oppenheimer maintains Q32 Bio at Outperform, $20 target - Investing.com India
Oppenheimer maintains Q32 Bio at Outperform, $20 target By Investing.com - Investing.com UK
Wells Fargo & Company Lowers Q32 Bio (NASDAQ:QTTB) Price Target to $15.00 - Defense World
Q32 Bio price target lowered to $15 from $16 at Wells Fargo - TipRanks
Could Aehr Test Systems (AEHR)’s Current Volatility Hinder Its Future Potential? - Marketing Sentinel
Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures - TipRanks
Q32 Bio Reports Promising Trial Results and Financials - TipRanks
Q32 Bio: Q4 Earnings Snapshot - Midland Daily News
Q32 Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):